Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
6.66
+0.27 (4.23%)
At close: Oct 19, 2026, 4:00 PM EDT
6.67
+0.01 (0.15%)
After-hours: Oct 19, 2026, 7:59 PM EDT
Precigen Revenue
Precigen had revenue of $54.98M in the quarter ending June 30, 2026, with 6,322.66% growth. This brings the company's total for the last twelve months to $85.72M, up 1,875.05% year-over-year. In the year 2025, Precigen had annual revenue of $9.68M with 146.73% growth. That makes Precigen the 23,827th largest company in the world by revenue and 3,397th in the United States.
Revenue (ttm)
$85.72M
Revenue Growth
+1,875.05%
P/S Ratio
27.82
Revenue / Employee
$535,731
Employees
160
Market Cap
2.38B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.68M | 5.76M | 146.73% |
| Dec 31, 2024 | 3.93M | -2.30M | -36.95% |
| Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
| Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
| Dec 31, 2021 | 14.27M | -88.91M | -86.17% |
| Dec 31, 2020 | 103.18M | 12.46M | 13.73% |
| Dec 31, 2019 | 90.72M | -60.46M | -39.99% |
| Dec 31, 2018 | 151.18M | -68.29M | -31.11% |
| Dec 31, 2017 | 219.46M | 28.54M | 14.95% |
| Dec 31, 2016 | 190.93M | 17.32M | 9.98% |
| Dec 31, 2015 | 173.61M | 101.68M | 141.35% |
| Dec 31, 2014 | 71.93M | 71.13M | 8,891.25% |
| Dec 31, 2013 | 800.00K | -12.97M | -94.19% |
| Dec 31, 2012 | 13.77M | 5.76M | 71.90% |
| Dec 31, 2011 | 8.01M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.68B |
| Harmony Biosciences Holdings | 959.90M |
| ADMA Biologics | 512.28M |
| Aurinia Pharmaceuticals | 311.51M |
| Beam Therapeutics | 156.04M |
| Viridian Therapeutics | 71.13M |
| Recursion Pharmaceuticals | 54.86M |
| NewAmsterdam Pharma Company | 7.12M |
PGEN News
- 24 days ago - Precigen initiated with a Buy at B. Riley - TheFly
- 25 days ago - Precigen initiated with a Buy at B. Riley - TheFly
- 4 weeks ago - Precigen says FDA grants platform technology designation to AdenoVerse platform - TheFly
- 4 weeks ago - Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform - PRNewsWire
- 7 weeks ago - Precigen Q2 marked commercial inflection - TheFly
- 7 weeks ago - Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers - Accesswire
- 2 months ago - Precigen price target raised to $18 from $14 at H.C. Wainwright - TheFly
- 2 months ago - Precigen Earnings Call Transcript: Q2 2026 - Transcripts